Reference data : LOINC code

Filter


Clear filter

Results
104,672 results found
Loinc Number Component Property System Time aspect ScaleType MethodType Relat_nms loincStatus Long Common name answerList chngType DefinitionDescription dtLastCh exactCmspy exampleUnits exmplAnswers externalCopyrightNotice formula hl7FieldSubfieldId InpcPercentage ipccUnits loincClass loincFinal loincNum mapTo methodTyp molarMass naaccrId orderObs panelElements reference scope setRoot shortName source surveyQuestSrc surveyQuestText unitsRequired acssym relatedNames2 VersionLastChanged VersionFirstRelease ValidHL7AttachmentRequest PanelType AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
68452-2 Lactate dehydrogenase CCnc Synv fld Pt Qn Reaction: pyruvate to lactate   ACTIVE Lactate dehydrogenase [Enzymatic activity/volume] in Synovial fluid by Pyruvate to lactate reaction   MIN DefinitionDescription     arb U/L             CHEM   68452-2   Reaction: pyruvate to lactate     Both       0 LDH Snv P to L-cCnc       N   2-Hydroxypropanoic acid; 2-hydroxy-propionate; 2-hydroxy-propionic acid; Catalytic Concentration; Chemistry; Dehydrog; Dehyrdogenase; Joint aspirate; Joint fld; Joint flu; Joint fluid; L.D.H; Lact; Lactic acid; Lactic acid dehydrogenase; LD; LDH; L-lactate; L-lactate dehydrogenase; P to L; Point in time; QNT; Quan; Quant; Quantitative; Random; React; Rxn; SF; SNV; Syn; Syn fl; Synov; Synovial fluid; Tumor marker 2.7 2.38               U/L       0
68453-0 Lactate dehydrogenase CCnc Synv fld Pt Qn Reaction: lactate to pyruvate   ACTIVE Lactate dehydrogenase [Enzymatic activity/volume] in Synovial fluid by Lactate to pyruvate reaction   MIN DefinitionDescription     arb U/L             CHEM   68453-0   Reaction: lactate to pyruvate     Both       0 LDH Snv L to P-cCnc       N   2-Hydroxypropanoic acid; 2-hydroxy-propionate; 2-hydroxy-propionic acid; Catalytic Concentration; Chemistry; Dehydrog; Dehyrdogenase; Joint aspirate; Joint fld; Joint flu; Joint fluid; L to P; L.D.H; Lact; Lactic acid; Lactic acid dehydrogenase; LD; LDH; L-lactate; L-lactate dehydrogenase; Point in time; QNT; Quan; Quant; Quantitative; Random; React; Rxn; SF; SNV; Syn; Syn fl; Synov; Synovial fluid; Tumor marker 2.73 2.38               U/L       0
68454-8 Phenylbutazone SCnc Gast fld Pt Qn     ACTIVE Phenylbutazone [Moles/volume] in Gastric fluid   MIN DefinitionDescription     umol/L             DRUG/TOX   68454-8         Both       0 Phenylbutazone Gast-sCnc       N   Butacote; Butadion; Butadione; Butazolidin; Butazone; Butrex; c231; C57; Carudol; Cotylbutazone; DRUG/TOXICOLOGY; Drugs; Exiheudon N; GAST; Gastric contents; Gastric fluid; Inflazone; Intrabutazone; Kadol; Level; Novobutazone; Point in time; QNT; Quan; Quant; Quantitative; Random; Spondyril; Substance concentration; Ticinil 2.7 2.38               umol/L       0
68455-5 Observation Aper Vitr fld.spun Pt Nom     ACTIVE Appearance of Spun Vitreous fluid   NAM DefinitionDescription                   SPEC   68455-5         Both       0 Appearance spun Vitf       N   Appearance; Nominal; Point in time; Random; SPEC; spun Vitf; Vitf; Vitreous fluid; Vitreous humor; Vitreous humour 2.79 2.38                     Release 2.79: COMPONENT: Triggered by coll w SCT: component that the description is property like as in Color, Appearance, Osmolality have changed to Component: Observation, and Property: Color, or Appearance, or Osmolality, so forthââ?¬Â¦; 0
68456-3 Transplant preparation facility NPI ID Facility Pt Nom     TRIAL Transplant preparation facility NPI   MIN DefinitionDescription                   SURVEY.ESRD   68456-3                 0     ESRD.RQMT_266 Medicare provider number for item 32 N   Admin; ESRD; ESRD survey; Ident; Identifier; National Provider Identifier; Nominal; Point in time; Prep; Random; Survey; Transplant prep facility NPI 2.44 2.38       AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
68457-1 Enterovirus & Parechovirus A RNA Prid XXX Pt Nom Probe.amp.tar   ACTIVE Enterovirus and Parechovirus A RNA [Identifier] in Specimen by NAA with probe detection   MIN DefinitionDescription       Reported as positive for either Enterovirus or Parechovirus, negative for both or indeterminate.           MICRO   68457-1   Probe.amp.tar     Both       0 EV+PeV A RNA Spec NAA+probe       N   3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; Entero virus; Enterovirus; EV; EV+PeV A; EV+PeV A RNA; EV-PCR; HPeV A RNA; Human Parecho virus; ID; Identity or presence; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Ljungan virus; LV; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nominal; Nucleic acid sequence based analysis; Other; PCR; PeV; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; Ribonucleic acid; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified 2.69 2.38                     Updated Component from 'Human parechovirus' to 'Parechovirus A' according to the currently accepted nomenclature.http://www.picornaviridae.com/parechovirus/parechovirus.htm 0
68458-9 Trichomonas sp Prid XXX Pt Nom Organism specific culture   ACTIVE Trichomonas sp identified in Specimen by Organism specific culture   NAM DefinitionDescription                   MICRO   68458-9   Organism specific culture     Both       0 Trichomonas Spec Cult       N   C&S; Cult; Cultures; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Nominal; Other; Point in time; Random; Spec; species; spp; To be specified in another part of the message; Tric; Trich; Trichimoniasis; Trichomonad; Trichomonads; Trichomoniasis; Unspecified 2.79 2.38                     Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; 0
68459-7 pH LsCnc Periton fld Pt SemiQn Test strip   ACTIVE pH of Peritoneal fluid by Test strip   MAJ DefinitionDescription     pH             CHEM   68459-7   Test strip     Both       0 pH Prt Strip       N   Ascites; Ascitic fluid; Ascitis; Chemistry; Dip stick; Dipstick; Log molar concentration; Peritoneal fluid; Point in time; Prt; Random; SmQn 2.75 2.38               [pH]       0
6846-0 Latex glove extract buffered Ab.IgE ACnc Ser Pt Qn     ACTIVE Latex glove extract buffered IgE Ab [Units/volume] in Serum   MIN DefinitionDescription     kIU/L             ALLERGY   6846-0         Both       0 Ltx Glv Ext Buff IgE Qn       Y   ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Brazilian rubber tree; Hevea braziliensis; Immune globulin E; Immunoglobulin E; k082; k82; Ltx; Ltx Glv Ext; Ltx Glv Ext Buff; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR 2.73 1.0h(2)               k[IU]/L       0
68460-5 Picornavirus Ag PrThr Isolate Pt Ord IF   ACTIVE Picornavirus Ag [Presence] in Isolate by Immunofluorescence   MIN DefinitionDescription       positive, negative           MICRO   68460-5   IF     Both       0 Picornavirus Ag Islt Ql IF       N   ACIF; Anticomplement Immunofluorescence; Antigen; Antigens; DFA; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Islt; Isol; Microbiology; Ordinal; Picorna virus; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Time Resolved Fluorescence; TRF 2.56 2.38                     The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
68461-3 Payment source Type ^Patient Pt Nom ESRD   DEPRECATED Deprecated Payment source [ESRD]   MIN DefinitionDescription                   SURVEY.ESRD   68461-3   ESRD             0     ESRD.RQMT_213 Current Medical Coverage N   End Stage Renal Disease; ESRD survey; Nominal; Point in time; Random; Srce; Survey; Typ 2.7 2.38       AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
68462-1 Physician information - end stage renal disease form 2728 - Provider Pt -     TRIAL Physician information - end stage renal disease form 2728 Provider   MIN DefinitionDescription                   PANEL.SURVEY.ESRD   68462-1                 0         N   Dis; Diseases; Dz; End Stage Renal Disease (ESDR) pnl; End-stage renal disease; ESRD; ESRD survey; Kidney; Pan; Panel; Panl; Physician information form 2728; Pnl; Point in time; Random; Survey 2.38 2.38   Panel   AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
68463-9 Rilpivirine Susc Isolate Pt Ord Genotyping   ACTIVE Rilpivirine [Susceptibility] by Genotype method   MIN DefinitionDescription       Resistant Sensitive Resistance Possible           ABXBACT   68463-9   Genotyping     Both       0 Rilpivirine Islt Genotyp       N   ANTIBIOTIC SUSCEPTIBILITIES; AST; Genotype; Genotypic; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.73 2.38                     Corrected Scale from OrdQn to Ord because Genotyping does not produce a quantitative susceptibility result 0
68464-7 Insulin^1.25H post XXX challenge ACnc Ser/Plas Pt Qn     ACTIVE Insulin [Units/volume] in Serum or Plasma --1.25 hours post XXX challenge   MIN DefinitionDescription     uIU/mL Numeric           CHAL   68464-7         Observation       0 Insulin 1.25h p chal SerPl-aCnc       N   1 1/4 H; 1.25 hours; 1.25 Hr; 1.25h p chal; 75 min; 75 minutes; 75min; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; HUM; Humulin; IH7; Insul; Lente; NPH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Ultralente 2.7 2.38               u[IU]/mL       0
68465-4 Insulin^1.75H post XXX challenge ACnc Ser/Plas Pt Qn     ACTIVE Insulin [Units/volume] in Serum or Plasma --1.75 hours post XXX challenge   MIN DefinitionDescription     uIU/mL Numeric           CHAL   68465-4         Observation       0 Insulin 1.75h p chal SerPl-aCnc       N   1.75 hours; 1.75 Hr; 1.75h p chal; 105 min; 105 minutes; 105min; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; HUM; Humulin; IH7; Insul; Lente; NPH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Ultralente 2.7 2.38               u[IU]/mL       0
68466-2 Epstein-Barr virus-encoded RNA 1 PrThr Tiss Pt Ord Probe   ACTIVE Epstein-Barr virus-encoded RNA 1 [Presence] in Tissue by Probe   MIN DefinitionDescription       Positive Negative           MICRO   68466-2   Probe     Both       0 EBV-encoded RNA1 Tiss Ql Probe       N   DNA NUCLEIC ACID PROBE; DNA probe; EBER; EBER1; EBV; EBV-encoded RNA1; Epstein-Barr virus; Epstn; HHV-4; human herpesvirus 4; i; ID; Infectious Disease; InfectiousDisease; Microbiology; Mono; Mononucleosis; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; Tissue; Tissue, unspecified 2.63 2.38                     The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
68467-0 APOB+LDLR+PCSK9 gene targeted mutation analysis Prid Bld/Tiss Pt Nom Molgen   ACTIVE APOB+LDLR+PCSK9 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal   MIN DefinitionDescription       Listing of identified gene mutations           MOLPATH.MUT   68467-0   Molgen     Both       0 APOB+LDLR+PCSK9 gene Mut Anl Bld/T       N   Blood; Convertase subtilisin/kexin type 9 preproprotein; FH3; Genetics; HCHOLA3; Heredity; Heritable; Hypercholesterolemia, autosomal dominant 3; Identity or presence; Inherited; LDLCQ1; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; NARC1; NARC-1; Neural apoptosis regulated convertase 1; Neural apoptosis-regulated convertase 1; Nominal; PC9; PCR; Point in time; Proprotein convertase PC9; Proprotein convertase subtilisin/kexin type 9; Random; Subtilisin/kexin-like protease PC9; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue 2.73 2.38                     Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section. 0
68468-8 Attending physician NPI ID Provider Pt Nom     ACTIVE Attending physician NPI Provider   MIN DefinitionDescription                   SURVEY.ESRD   68468-8         Observation       0         N   ESRD; ESRD survey; Ident; Identifier; National Provider Identifier; Nominal; Point in time; Random; Survey 2.63 2.38                       0
68469-6 Consultation note Find Hospital Pt Doc Pastoral care   ACTIVE Pastoral care Hospital Consult note   MIN DefinitionDescription                   DOC.ONTOLOGY   68469-6   Pastoral care     Both       0 Pastoral Care Hosp Consult note       N   Consult note; Continuity assessment record and evaluation; DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; Hosp; Inpatient; notes; Point in time; Random; Visit note 2.58 2.38                       0
6847-8 Chenopodium ambrosioides Ab.IgE ACnc Ser Pt Qn     ACTIVE Mexican tea IgE Ab [Units/volume] in Serum   MIN DefinitionDescription     kIU/L             ALLERGY   6847-8         Both       0 Mexican tea IgE Qn       Y   ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Immune globulin E; Immunoglobulin E; Mexican tea; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; w35 2.73 1.0h(2)               k[IU]/L       0
68470-4 Initial evaluation note Find Hospital Pt Doc Respiratory therapy   ACTIVE Respiratory therapy Hospital Initial evaluation note   MIN DefinitionDescription                   DOC.ONTOLOGY   68470-4   Respiratory therapy     Both       0 Resp therapy Hosp Initial eval note       N   Assessment; DOC.ONT; Document; Encounter; Eval; Eval note; Evaluation and management; Evaluation and management note; Finding; Findings; H&P; History and physical; Hosp; Initial eval note; Inpatient; Lung; notes; Point in time; Pulmonary; Pulmonology; Random; Resp therapy; Respiratory; Visit note 2.5 2.38                       0
68471-2 Admission evaluation note Find Hospital Pt Doc Cardiovascular disease   ACTIVE Cardiology Hospital Admission evaluation note   MIN DefinitionDescription                   DOC.ONTOLOGY   68471-2   Cardiovascular disease     Both       0 Cardiology Hosp Admit eval note       N   Admit eval note; Assessment; cardiology; cards; CVD; Dis; Diseases; DOC.ONT; Document; Dz; Encounter; Eval; Eval note; Evaluation and management; Evaluation and management note; Finding; Findings; H&P; History and physical; Hosp; Inpatient; notes; Point in time; Random; Visit note 2.5 2.38                       0
68472-0 Progress note Find Hospital Pt Doc Cardiovascular disease   ACTIVE Cardiology Hospital Progress note   MIN DefinitionDescription                   DOC.ONTOLOGY   68472-0   Cardiovascular disease     Both       0 Cardiology Hosp Prog note       N   cardiology; cards; CVD; Dis; Diseases; DOC.ONT; Document; Dz; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; Hosp; Inpatient; notes; Point in time; Prog note; Random; subsequent evaluation; subsequent visit evaluation; Visit note 2.73 2.38                       0
68473-8 Progress note Find Hospital Pt Doc Critical care medicine.attending   ACTIVE Critical care medicine Attending Hospital Progress note   MIN DefinitionDescription                   DOC.ONTOLOGY   68473-8   Critical care medicine.attending     Both       0 CCM Attend Hosp Prog note       N   CCM; CCM Attend; Continuity assessment record and evaluation; DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; Hosp; Inpatient; notes; Point in time; Prog note; Random; subsequent evaluation; subsequent visit evaluation; Visit note 2.73 2.38                     Updated "Physician attending" in Method to "Attending" based on Clinical LOINC Committee review and approval (10/2018). 0
68474-6 Restraint note Find Hospital Pt Doc Physician   ACTIVE Physician Hospital Restraint note   MIN DefinitionDescription                   DOC.ONTOLOGY   68474-6   Physician     Both       0 MD Hosp Restraint note       N   DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; Hosp; Inpatient; M.D.; MD; notes; Point in time; Random; Visit note 2.58 2.38                       0
104,672 results found